Clicky

Shanghai Henlius Biotech Inc(2696)

Description: Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.


Keywords: Medicine Cancer Biopharmaceutical Clinical Medicine Drugs Solid Tumors Autoimmune Disease Breast Cancer Rheumatoid Arthritis Lymphoma Melanoma Osteoporosis Multiple Myeloma Hepatocellular Carcinoma Protein Kinase Inhibitor Head And Neck Cancer Non Small Cell Lung Carcinoma Wet Age Related Macular Degeneration Chronic Lymphocytic Leukemia Plaque Psoriasis Gastric Cancer Metastatic Colorectal Cancer Renal Cell Carcinoma Spondylitis Uveitis Monoclonal Antibody Therapy Trastuzumab Squamous Cell Carcinoma Non Hodgkin Lymphoma Ophthalmic Diseases Adalimumab Metastatic Non Small Cell Lung Cancer Cetuximab Non Squamous Non Small Cell Lung Cancer Treatment Of Gastric Cancer Bevacizumab Rituximab

Home Page: www.henlius.com

Innov Tower (Capitaland Building)
Shanghai, 200233
China
Phone: 86 21 3339 5800


Officers

Name Title
Mr. Wenjie Zhang CEO & Chairman
Mr. Jason Zhu Pres
Dr. Shi-Kau Liu Co-founder & Head of Strategy Advisory Committee
Dr. Wei-Dong Jiang Co-Founder & Co-Head of Innovative Advisory Committee
Mr. Xinlei Li CFO & VP
Ms. Huang Wei Sr. VP & COO
Dr. Jifeng Zhang CTO & Sr. VP
Mr. James Liu VP of Legal & Compliance
Mr. Wallis Zeng VP of Sales
Ms. Jessie Li VP & Chief Human Resource Officer

Exchange: HK

Country: HK

Currency: Hong Kong Dollar (HK$)

Forward PE: 21.2314
Trailing PE: 0
Price-to-Book MRQ: 3.2491
Price-to-Sales TTM: 3.0309
IPO Date:
Fiscal Year End: December
Full Time Employees: 2933
Back to stocks